Approval

China approves Bayer's HER2 inhibitor for first-line HER2-mutant lung cancer

Bayer's oral HER2 tyrosine kinase inhibitor, already cleared in China after prior therapy, is now approved as monotherapy for untreated advanced lung cancer carrying HER2 mutations. In 73 treatment-naive patients from the SOHO-01 study, 75.3% responded and 72.7% of responders stayed in response for six months or more.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call